BETA
Your AI-Trained Oncology Knowledge Connection!
Early ESR1 Mutation Detection via ctDNA Monitoring Could Enhance Treatment Adaptation in HR+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.
Dr Tolaney on the Optimal Timing of ESR1 Testing in HR+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses the ideal time for patients with HR-positive breast cancer to undergo genetic testing for ESR1 mutations.
Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer
Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.
Dr Hamilton on Treatment Selection After Progression on Frontline CDK4/6 Inhibition in HR+ Breast Cancer
Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.
T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer
EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC
Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer
Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer
%20(1).jpg?fit=crop&auto=format)
